Resectable Head and Neck Squamous Cell Carcinoma Clinical Trials in Boston, Massachusetts
2 recruitingBoston, Massachusetts
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled193 locationsNCT04534205
Recruiting
Phase 2
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Head and Neck CancerHead and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma+2 more
Dana-Farber Cancer Institute28 enrolled2 locationsNCT05726370